News & Updates
Showing Hepatology articles
Showing

Vebicorvir plus Nrtl safe, well tolerated in patients with chronic HBV infection
Treatment with vebicorvir (VBR) plus nucleos(t)ide reverse transcriptase inhibitors (NrtIs) among virologically suppressed patients with chronic hepatitis B virus (HBV) is well tolerated and has a favourable safety profile, according to a 24-week study.

STRIDE regimen benefit in unresectable HCC consistent across baseline liver function
The overall survival (OS) benefit observed with the STRIDE regimen compared with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) is consistent regardless of baseline liver function, according to exploratory analysis of data from the phase III HIMALAYA trial presented at ESMO GI 2022.

Enhanced liver fibrosis score stratifies HCC risk in CHB patients after HBsAg seroclearance
Researchers at the University of Hong Kong (HKU) have identified enhanced liver fibrosis (ELF) score as a tool to stratify hepatocellular carcinoma (HCC) risk in chronic hepatitis B (CHB) patients after HBsAg seroclearance (SC).






